NHMRC Glaucoma Guidelines - ANZGIG
NHMRC Glaucoma Guidelines - ANZGIG
NHMRC Glaucoma Guidelines - ANZGIG
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>NHMRC</strong> GUIDELINES FOR THE SCREENING, PROGNOSIS, DIAGNOSIS, MANAGEMENT AND PREVENTION OF GLAUCOMA<br />
Chapter 9 – Medication<br />
Table 9.3: Summary of medications and their respective contraindications, precautions and interactions<br />
Class<br />
Contraindications<br />
Precautions<br />
to use<br />
Interactions<br />
Prostaglandin Analogues<br />
Latanoprost<br />
Travoprost<br />
Bimatoprost<br />
Intraocular inflammation<br />
(iritis, uveitis)—relatively<br />
contraindicated if active;<br />
monitor carefully if<br />
history of disease.<br />
Aphakia, pseudophakia,<br />
torn posterior lens or<br />
capsule, known risk<br />
factors for macular<br />
oedema—increased<br />
risk of developing<br />
macular oedema<br />
NSAIDs<br />
(eye drops)—<br />
reduce efficacy<br />
of prostaglandin<br />
analogues<br />
Beta-blockers<br />
Non-selective agents<br />
Timolol<br />
Levobunolol<br />
Selective agents<br />
Betaxolol<br />
Reversible airways disease,<br />
e.g. asthma—use is generally<br />
contraindicated, however<br />
cardio-selective agents,<br />
i.e. betaxolol, may be used<br />
with care.<br />
Brady arrhythmia<br />
Heart block<br />
Diabetes<br />
Hyperthyroidism<br />
Cardiac Failure<br />
COPD—betaxolol<br />
preferred<br />
Depression—<br />
may aggravate<br />
Elderly—Systemic<br />
adverse effects are<br />
more common,<br />
e.g. hypotension<br />
(may cause falls)<br />
Children—<br />
May cause bradycardia,<br />
bronchospasm and<br />
hypoglycaemia<br />
Systemic betablockers—potential<br />
additive effects<br />
Catecholaminedepleting<br />
medications<br />
Medications that<br />
reduce BP, cardiac<br />
contractility and<br />
conduction—<br />
potential additive<br />
effects<br />
Verapamil—<br />
only use under<br />
specialist supervision<br />
Alpha 2<br />
-agonists<br />
Brimonidine<br />
Apraclonidine<br />
Monoamine oxidase<br />
inhibitors therapy<br />
Children younger than<br />
two years—use with caution<br />
in children younger than<br />
seven years<br />
Severe cardiovascular<br />
disease—may worsen;<br />
use with caution.<br />
Depression—<br />
may aggravate<br />
CNS depressant:<br />
Alcohol<br />
Barbiturates<br />
Opiates<br />
Sedatives<br />
Anaesthetics<br />
Tricyclic antidepressants<br />
Hypotensive<br />
agents— potential<br />
additive effect<br />
Carbonic Anhydrase<br />
Inhibitors<br />
Topical<br />
Dorzolamide<br />
Brinzolamide<br />
Corneal grafts, endothelial<br />
dystrophy—may cause<br />
corneal oedema and<br />
precipitate corneal<br />
decompensation.<br />
Allergy to sulfonamides—<br />
may increase risk of<br />
allergy to carbonic<br />
anhydrase inhibitors<br />
Severe hepatic/renal<br />
impairment<br />
None reported, but<br />
potential exists for<br />
similar interactions as<br />
for systemic carbonic<br />
anhydrase inhibitors<br />
114 National Health and Medical Research Council